2010
DOI: 10.1200/jco.2010.28.15_suppl.1081
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
26
0

Year Published

2010
2010
2014
2014

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(26 citation statements)
references
References 0 publications
0
26
0
Order By: Relevance
“…Phase ii trials in patients with metastatic breast cancer [42][43][44] Patients had to have received both an anthracycline and a taxane, but additional treatments were also permitted; other eligibility criteria were standard, but pre-existing neuropathy Grade 1 42 or 1-2 43 was permitted. Objective response rate was the primary endpoint in all three studies, and responses were independently reviewed.…”
Section: -39mentioning
confidence: 99%
See 1 more Smart Citation
“…Phase ii trials in patients with metastatic breast cancer [42][43][44] Patients had to have received both an anthracycline and a taxane, but additional treatments were also permitted; other eligibility criteria were standard, but pre-existing neuropathy Grade 1 42 or 1-2 43 was permitted. Objective response rate was the primary endpoint in all three studies, and responses were independently reviewed.…”
Section: -39mentioning
confidence: 99%
“…Encouraging Phase II [42][43][44] data have been supplemented by recent Phase III 45 data showing eribulin to be the first monotherapy to prolong survival in women with heavily pretreated metastatic breast cancer.…”
Section: Introductionmentioning
confidence: 99%
“…The 21-day dosing schedule was also investigated in 81 Japanese patients pretreated with an anthracycline and a taxane (median of 3 prior chemotherapy regimens), who received eribulin mesylate 1.4 mg/m 2 on days 1 and 8. The ORR was 21.3% and the median duration of response was 3.9 months (20).…”
Section: Clinical Studiesmentioning
confidence: 96%
“…Phase II testing of eribulin mesylate was subsequently conducted in women with heavily pretreated breast cancer (18)(19)(20). It was hypothesized that eribulin might have activity in breast cancer refractory to other microtubuletargeted drugs, such as taxanes, given its unique mechanism of action and impressive preclinical activity.…”
Section: Clinical Studiesmentioning
confidence: 99%
“…Grade 3 peripheral neuropathy occurred in 3.7% of patients (no grade 4). 28 These data are summarized in Table 1.…”
mentioning
confidence: 99%